What is malaria?
Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small
Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small
Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world’s first COVID-19 characterisation study. Cathal explains what these results mean for Open Orphan, plans
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the
As the Omicron variant of the coronavirus continues to sweep across the United States, another important question has emerged for scientists worldwide: Will more transmission equal more long COVID cases?
A little-known disease called RSV with symptoms similar to a cold and elements easily mistaken for Covid puts thousands of UK kids in hospital each year – now warnings are being
Non-clinical testing is conducted throughout all phases of drug development to assess the safety profile and pharmacokinetic/toxico- kinetic (PK/TK) characteristics of drug candidates. If performed well, it can identify key
Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement
The Challenge Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company